Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Which are the two Spanish stock funds that are sweeping this summer
Two investment funds have accumulated a return of between 10.5% and 15.5% since the beginning of June. So far this year they have gained more than 15.83%.
Cobas and Azvalor increase their assets by more than 25% in 2026
El rally del 'value' y los flujos de dinero nuevo impulsan el crecimiento de las dos gestoras, que multiplican por cuatro el avance del conjunto del sector. Leer
GBP/JPY Price Forecast: Bulls stall near 216.00 as RSI flattens
The GBP/JPY consolidates at familiar levels on Tuesday, virtually unchanged near 216.00, with the cross-pair seesawing within the 215.85-216.22 range, as neither buyers nor sellers are able to clear…
Broadcom vs. Nvidia: 1 Metric Shows Which Artificial Intelligence (AI) Chipmaker Is the Better Bargain
Broadcom's sales are expected to grow dramatically in 2027.
Anterix (ATEX) Q1 2027 Earnings Call Transcript
Revenue grew to $2 million as spectrum monetization opportunities expand.
US Antimony (UAMY) Q2 2026 Earnings Call Transcript
Antimony prices collapsed, but zeolite surged 110% and government contracts accelerate.